Submitted:
06 December 2023
Posted:
06 December 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Data sources and study population
2.2. Statistical analysis
3. Results
3.1. Changes in mortality rates among people with disabilities before and after the COVID-19 pandemic
3.2. Changes in causes of death among people with disabilities before and after the COVID-19 pandemic
3.3. Changes in cause of death related to COVID-19 in people with disabilities after the COVID-19 pandemic.
3.3.1. Diseases of the nervous system (G00-G99)
3.3.2. Certain infectious and parasitic diseases (A00-B99)
3.3.3. Diseases of the respiratory system (J00-J99)
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organiztion. WHO Director-General's statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV). Available online: https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov) (accessed on 7 August 2023).
- Korea Disease Control and Prevention Agency. Current status of domestic outbreak of COVID-19. Available online: https://www.kdca.go.kr/board/board.es?mid=a20501010000&bid=0015&act=view&list_no=366403 (accessed on 7 August 2023).
- Korea Disease Control and Prevention Agency. Social distancing adjustment plan. Available online: https://www.kdca.go.kr/board/board.es?mid=a20501020000&bid=0015&list_no=719317&cg_code=C01&act=view&nPage=1 (accessed on 7 August 2023).
- Korean Culture and Information Service. Declaring the end of COVID-19...President Yoon "Restoration of daily life after 3 years and 4 months". Available online: https://www.kocis.go.kr/koreanet/view.do?seq=1044801 (accessed on 7 August 2023).
- Yanez, N.D.; Weiss, N.S.; Romand, J.A.; Treggiari, M.M. COVID-19 mortality risk for older men and women. BMC Public Health 2020, 20, 1742. [Google Scholar] [CrossRef] [PubMed]
- Zhao, H.L.; Huang, Y.M.; Huang, Y. Mortality in Older Patients with COVID-19. J Am Geriatr Soc 2020, 68, 1685–1687. [Google Scholar] [CrossRef] [PubMed]
- hahid, Z.; Kalayanamitra, R.; McClafferty, B.; Kepko, D.; Ramgobin, D.; Patel, R.; Aggarwal, C.S.; Vunnam, R.; Sahu, N.; Bhatt, D. , et al. COVID-19 and Older Adults: What We Know. J Am Geriatr Soc 2020, 68, 926–929. [Google Scholar] [CrossRef] [PubMed]
- Demetriou, C.A.; Achilleos, S.; Quattrocchi, A.; Gabel, J.; Critselis, E.; Constantinou, C.; Nicolaou, N.; Ambrosio, G.; Bennett, C.M.; Le Meur, N. , et al. Impact of the COVID-19 pandemic on total, sex- and age-specific all-cause mortality in 20 countries worldwide during 2020: results from the C-MOR project. Int J Epidemiol 2023, 52, 664–676. [Google Scholar] [CrossRef] [PubMed]
- Akter, S. The gender gap in COVID-19 mortality in the United States. Feminist Economics 2021, 27, 30–47. [Google Scholar] [CrossRef]
- Jain, V.K.; Iyengar, K.; Vaish, A.; Vaishya, R. Differential mortality in COVID-19 patients from India and western countries. Diabetes Metab Syndr 2020, 14, 1037–1041. [Google Scholar] [CrossRef] [PubMed]
- ishra, V.; Seyedzenouzi, G.; Almohtadi, A.; Chowdhury, T.; Khashkhusha, A.; Axiaq, A.; Wong, W.Y.E.; Harky, A. Health Inequalities During COVID-19 and Their Effects on Morbidity and Mortality. J Healthc Leadersh 2021, 13, 19–26. [Google Scholar] [CrossRef] [PubMed]
- Kissler, S.; Tedijanto, C.; Lipsitch, M.; Grad, Y.H. Social distancing strategies for curbing the COVID-19 epidemic. MedRxiv 2020, 2020–03. [Google Scholar] [CrossRef]
- Aslam, F. COVID-19 and importance of social distancing. 2020. [Google Scholar] [CrossRef]
- Russell, F.M.; Greenwood, B. Who should be prioritised for COVID-19 vaccination. Hum Vaccin Immunother 2021, 17, 1317–1321. [Google Scholar] [CrossRef]
- Saadi, N.; Chi, Y.L.; Ghosh, S.; Eggo, R.M.; McCarthy, C.V.; Quaife, M.; Dawa, J.; Jit, M.; Vassall, A. Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review. BMC Med 2021, 19, 318. [Google Scholar] [CrossRef] [PubMed]
- Güner, R.; Hasanoğlu, I.; Aktaş, F. COVID-19: Prevention and control measures in community. Turk J Med Sci 2020, 50, 571–577. [Google Scholar] [CrossRef] [PubMed]
- irum, T.; Lentiro, K.; Geremew, M.; Migora, B.; Shewamare, S. Global strategies and effectiveness for COVID-19 prevention through contact tracing, screening, quarantine, and isolation: a systematic review. Trop Med Health 2020, 48, 91. [Google Scholar] [CrossRef] [PubMed]
- Emmanuel, F.; Hassan, A.; Ahmad, A.; Reza, T.E. Pakistan's COVID-19 Prevention and Control Response Using the World Health Organization's Guidelines for Epidemic Response Interventions. Cureus 2023, 15, e344802023–15. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Heo, N.; Kang, H. Sex-Based Differences in Outcomes of Coronavirus Disease 2019 (COVID-19) in Korea. Asian Nurs Res (Korean Soc Nurs Sci). [CrossRef] [PubMed]
- Kang, S.J.; Jung, S.I. Age-Related Morbidity and Mortality among Patients with COVID-19. Infect Chemother 2020, 52, 154–164. [Google Scholar] [CrossRef]
- Ministry of Government Legislation. Database: Act on Welfare of Persons with Disabilities. Available online: https://www.law.go.kr/LSW/eng/engLsSc.do?menuId=2§ion=lawNm&query=South+Korea+%E2%80%93+Welfare+law+for+Persons+with+Disabilities&x=0&y=0#liBgcolor0[] (accessed on 10 August 2023).
- Number of The Registered Disabled-by Year, Types of Disability and Gender (The Whole Country). Available online: https://kosis.kr/statHtml/statHtml.do?orgId=117&tblId=DT_11761_N001&conn_path=I2&language=en (accessed on 10 November 2023).
- Landes, S.D.; Turk, M.A.; Ervin, D.A. COVID-19 case-fatality disparities among people with intellectual and developmental disabilities: Evidence from 12 US jurisdictions. Disabil Health J 2021, 14, 101116. [Google Scholar] [CrossRef] [PubMed]
- Kuper, H.; Smythe, T. Are people with disabilities at higher risk of COVID-19-related mortality?: a systematic review and meta-analysis. Public Health 2023, 222, 115–124. [Google Scholar] [CrossRef] [PubMed]
- Seid, A.A.; Woday Tadesse, A.; Hasen, A.A. Severity and mortality of COVID-19 among people with disabilities: protocol for a systematic review and meta-analysis. BMJ Open 2022, 12, e0614382022–12. [Google Scholar] [CrossRef]
- ariyer, G.; Ataman, M.G.; Mangla, S.K.; Kazancoglu, Y.; Dora, M. Big data analytics and the effects of government restrictions and prohibitions in the COVID-19 pandemic on emergency department sustainable operations. Ann Oper Res. [CrossRef]
- hen, B.; Wang, M.; Huang, X.; Xie, M.; Pan, L.; Liu, H.; Liu, Z.; Zhou, P. Changes in Incidence of Notifiable Infectious Diseases in China Under the Prevention and Control Measures of COVID-19. Front Public Health 2021, 9, 728768. [Google Scholar] [CrossRef] [PubMed]
- Dey, A.; Roy, I.; Chakrabartty, A.K.; Choudhury, A.; Lahiri, A. Changing patterns of household transmission of tuberculosis in an eastern state of India: The impact of COVID19 pandemic. Indian J Tuberc 2022, 69, 682–689. [Google Scholar] [CrossRef] [PubMed]
- arcia-Olive, I.; Lopez Seguí, F.; Hernandez Guillamet, G.; Vidal-Alaball, J.; Abad, J.; Rosell, A. Impact of the COVID-19 pandemic on diagnosis of respiratory diseases in the Northern Metropolitan Area in Barcelona (Spain). Med Clin (Engl Ed) 2023, 160, 392–396. [Google Scholar] [CrossRef]
- Soriano, J.B.; Peláez, A.; Fernández, E.; Ancochea, J. Impact of the COVID-19 pandemic in mortality due to respiratory diseases: A comparative analysis of 2021 and 2020 vs 2019 in Spain. Med Clin (Barc) 2023, 161, 192–198. [Google Scholar] [CrossRef] [PubMed]
| Year | People with disability | General population | Absolute difference (times) | |||||||
| All death | Crude mortality rate | Total COVID-19 death | COVID-19 Infection fatality rate | All death |
Crude mortality rate | Total COVID-19 death | COVID-19 Infection fatality rate | Crude mortality rate |
COVID-19 Infection fatality rate | |
| 2017 | 69,478 | 2,750.6 | NA | NA | 285,534 | 557.3 | NA | NA | 4.9 | NA |
| 2018 | 74,957 | 2,927.7 | NA | NA | 298,820 | 582.5 | NA | NA | 5.0 | NA |
| 2019 | 75,402 | 2,903.4 | NA | NA | 295,110 | 574.8 | NA | NA | 5.1 | NA |
| 2020 | 78,879 | 3,009.6 | 240 | 9.2 | 304,948 | 593.9 | 950 | 1.9 | 5.1 | 4.8 |
| 2021 | 83,858 | 3,181.1 | 1,414 | 53.6 | 317,680 | 618.9 | 5,030 | 9.8 | 5.1 | 5.5 |
| 2022 | 102,916 | 3,885.4 | 10,513 | 396.9 | 372,939 | 727.6 | 31,280 | 61.0 | 5.3 | 6.5 |
| ICD-10 categories | 2017 (N= 69,478) |
2018 (N= 74,957) |
2019 (N= 75,402) |
2020 (N= 78,879) |
2021 (N= 83,858) |
2022 (N= 102,916) |
|||||||||||||
| n (%) | CSMR | SMR | n (%) | CSMR | SMR | n (%) | CSMR | SMR | n (%) | CSMR | SMR | n (%) | CSMR | SMR | n (%) | CSMR | SMR | ||
| A00-B99 | 2,178 (3.13) |
86.2 | 24.7 | 2,565 (3.42) |
100.2 | 27.7 | 2,562 (3.40) |
98.7 | 25.6 | 2,953 (3.74) |
112.7 | 31.4 | 3,154 (3.76) |
119.6 | 27.2 | 3,254 (3.16) |
122.8 | 28.3 | |
| C00-D48 | 14,436 (20.78) |
571.5 | 167.7 | 14,886 (19.86) |
581.4 | 162.5 | 15,715 (20.84) |
605.1 | 165.7 | 15,981 (20.26) |
609.7 | 161.8 | 16,353 (19.50) |
620.3 | 155.0 | 16,616 (16.15) |
627.3 | 162.4 | |
| D50-D89 | 179 (0.26) |
7.1 | 2.2 | 214 (0.29) |
8.3 | 3.4 | 206 (0.27) |
7.9 | 3.3 | 224 (0.28) |
8.5 | 3.8 | 223 (0.27) |
8.5 | 2.5 | 218 (0.21) |
8.2 | 4.2 | |
| E00-E90 | 3,824 (5.50) |
151.4 | 66.0 | 3,972 (5.30) |
155.1 | 43.2 | 3,589 (4.76) |
138.2 | 39.5 | 3,766 (4.77) |
143.7 | 39.7 | 3,869 (4.61) |
146.8 | 42.2 | 4,953 (4.81) |
187.0 | 52.1 | |
| F00-F99 | 1,155 (1.66) |
45.7 | 11.3 | 1,089 (1.45) |
42.5 | 9.8 | 1,077 (1.43) |
41.5 | 8.9 | 1,011 (1.28) |
38.6 | 9.8 | 886 (1.06) |
33.6 | 8.5 | 927 (0.90) |
35.0 | 9.6 | |
| G00-G99 | 3,854 (5.55) |
152.6 | 89.3 | 4,366 (5.82) |
170.5 | 96.0 | 4,290 (5.69) |
165.2 | 84.9 | 4,643 (5.89) |
177.2 | 73.4 | 5,085 (6.06) |
192.9 | 84.2 | 6,520 (6.34) |
246.1 | 101.0 | |
| H00-H59 | 0 (0.00) |
NA | NA | 4 (0.01) |
0.2 | 0.1 | 1 (0.00) |
0.04 | 0.005 | 0 (0.00) |
NA | NA | 0 (0.00) |
NA | NA | 0 (0.00) |
NA | NA | |
| H60-H95 | 3 (0.00) |
0.1 | 0.01 | 6 (0.01) |
0.2 | 0.04 | 5 (0.01) |
0.2 | 0.02 | 2 (0.00) |
0.08 | 0.007 | 6 (0.01) |
0.2 | 0.2 | 5 (0.00) |
0.2 | 0.017 | |
| I00-I99 | 17,592 (25.32) |
696.5 | 162.8 | 18,396 (24.54) |
718.5 | 163.3 | 17,795 (23.60) |
685.2 | 154.6 | 18,613 (23.60) |
710.2 | 150.9 | 18,920 (22.56) |
717.7 | 143.9 | 21,550 (20.94) |
813.6 | 157.5 | |
| J00-J99 | 9,441 (13.59) |
373.8 | 82.3 | 11,181 (14.92) |
436.7 | 91.5 | 11,364 (15.07) |
437.6 | 87.4 | 11,315 (14.34) |
431.7 | 82.3 | 11,648 (13.89) |
441.9 | 77.3 | 13,368 (12.99) |
504.7 | 92.8 | |
| K00-K93 | 2,760 (3.97) |
109.3 | 38.7 | 2,888 |
112.8 | 42.2 | 2,887 (3.83) |
111.2 | 39.4 | 3,083 (3.91) |
117.6 | 41.1 | 3,200 (3.82) |
121.4 | 42.3 | 3,535 (3.43) |
133.5 | 47.2 | |
| L00-L99 | 191 (0.27) |
7.6 | 1.7 | 207 (0.28) |
8.1 | 1.7 | 188 (0.25) |
7.2 | 1.6 | 224 (0.28) |
8.5 | 2.2 | 191 (0.23) |
7.2 | 1.7 | 186 (0.18) |
7.0 | 1.5 | |
| M00-M99 | 441 (0.63) |
17.5 | 5.7 | 429 (0.57) |
16.8 | 4.8 | 447 (0.59) |
17.2 | 5.1 | 458 (0.58) |
17.5 | 4.8 | 463 (0.55) |
17.6 | 5.0 | 547 (0.53) |
20.7 | 5.8 | |
| N00-N99 | 3,376 (4.86) |
133.7 | 34.6 | 3,644 (4.86) |
142.3 | 36.1 | 3,989 (5.29) |
153.6 | 34.7 | 4,223 (5.35) |
161.1 | 37.1 | 4,411 (5.26) |
167.3 | 35.7 | 4,754 (4.62) |
179.5 | 41.3 | |
| O00-O99 | 2 (0.00) |
0.1 | 0.2 | 0 (0.00) |
NA | NA | 1 (0.00) |
0.04 | 0.2 | 1 (0.00) |
0.04 | 0.1 | 0 (0.00) |
NA | NA | 2 (0.00) |
0.1 | 0.3 | |
| P00-P96 | 2 (0.00) |
0.1 | 1.6 | 1 (0.00) |
0.04 | 0.8 | 2 (0.00) |
0.08 | 1.4 | 1 (0.00) |
0.04 | 0.2 | 3 (0.00) |
0.1 | 1.8 | 7 (0.01) |
0.3 | 3.9 | |
| Q00-Q99 | 112 (0.16) |
4.4 | 18.3 | 106 (0.14) |
4.1 | 14.8 | 110 (0.15) |
4.2 | 14.6 | 112 (0.14) |
4.3 | 17.9 | 116 (0.14) |
4.4 | 14.3 | 129 (0.13) |
4.9 | 21.1 | |
| R00-R99 | 5,424 (7.81) |
214.7 | 53.7 | 6,312 (8.42) |
246.5 | 59.3 | 6,583 (8.73) |
253.5 | 59.8 | 7,448 (9.44) |
284.2 | 60.4 | 9,449 (11.27) |
358.4 | 71.6 | 11,077 (10.76) |
418.2 | 77.1 | |
| U00-U18 | 0 (0.00) |
NA | NA | 0 (0.00) |
NA | NA | 0 (0.00) |
NA | NA | 240 (0.30) |
9.2 | 1.7 | 1,414 (1.69) |
53.6 | 12.3 | 10,513 (10.22) |
396.9 | 85.3 | |
| V01-Y98 | 4,507 (6.49) |
178.4 | 93.0 | 4,691 (6.26) |
183.2 | 90.8 | 4,591 (6.09) |
176.8 | 89.7 | 4,581 (5.81) |
174.8 | 91.9 | 4,467 (5.33) |
169.5 | 77.4 | 4,755 (4.62) |
179.5 | 81.6 | |
| Diseases of the nervous system (G00-G99) |
2017 (N = 3,854) |
2018 (N = 4,366) |
2019 (N = 4,290) |
2020 (N = 4,643) |
2021 (N = 5,085) |
2022 (N = 6,520) |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Inflammatory diseases of the central nervous system (G00-G09) | 55 (1.43) | 69 (1.58) | 72 (1.68) | 63 (1.36) | 71 (1.40) | 90 (1.38) |
| Systemic atrophies primarily affecting the central nervous system (G10-G14) | 408 (10.59) | 432 (9.89) | 409 (9.53) | 370 (7.97) | 409 (8.04) | 496 (7.61) |
| Extrapyramidal and movement disorders (G20-G26) | 1,564 (40.58) | 1,749 (40.06) | 1,490 (34.73) | 1,589 (34.22) | 1,769 (34.79) | 2,070 (31.75) |
| Other degenerative diseases of the nervous system (G30-G32) | 1,043 (27.06) | 1,318 (30.19) | 1,501 (34.99) | 1,811 (39.00) | 1,935 (38.05) | 2,789 (42.78) |
| Demyelinating diseases of the central nervous system (G35-G37) | 16 (0.42) | 22 (0.50) | 14 (0.33) | 21 (0.45) | 13 (0.26) | 24 (0.37) |
| Episodic and paroxysmal disorders (G40-G47) | 224 (5.81) | 238 (5.45) | 231 (5.38) | 220 (4.74) | 251 (4.94) | 312 (4.79) |
| Nerve, nerve root, and plexus disorders (G50-G59) | 1 (0.03) | 1 (0.02) | 0 (0.00) | 2 (0.04) | 5 (0.10) | 3 (0.05) |
| Polyneuropathies and other disorders of the peripheral nervous system (G60-G64) | 14 (0.36) | 18 (0.41) | 11 (0.26) | 13 (0.28) | 25 (0.49) | 22 (0.34) |
| Diseases of myoneural junction and muscle (G70-G73) | 132 (3.43) | 133 (3.05) | 117 (2.73) | 114 (2.46) | 119 (2.34) | 119 (1.83) |
| Cerebral palsy and other paralytic syndromes (G80-G83) | 149 (3.87) | 144 (3.30) | 156 (3.64) | 126 (2.71) | 114 (2.24) | 190 (2.91) |
| Other disorders of the nervous system (G90-G99) | 248 (6.43) | 242 (5.54) | 289 (6.74) | 314 (6.76) | 374 (7.35) | 405 (6.21) |
| n: number of deaths; CSMR: cause-specific mortality rate (per 100,000 people); SMR; age-adjusted standardized mortality rate (per 100,000 people); NA: Not Available | ||||||
| Certain infectious and parasitic diseases (A00-B99) | 2017 (N = 2,178) |
2018 (N =,2,565) |
2019 (N = 2,562) |
2020 (N = 2,953) |
2021 (N = 3,154) |
2022 (N = 3,254) |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Intestinal infectious diseases (A00-A09) | 265 (12.17) | 301 (11.73) | 282 (11.01) | 301 (10.19) | 297 (9.42) | 310 (9.53) |
| Tuberculosis (A15-A19) | 393 (18.04) | 412 (16.06) | 359 (14.01) | 351 (11.89) | 368 (11.67) | 336 (10.33) |
| Certain zoonotic bacterial diseases (A20-A28) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (0.03) |
| Other bacterial diseases (A30-A49) | 1,262 (57.94) | 1,558 (60.74) | 1,625 (63.43) | 2,036 (68.95) | 2,251 (71.37) | 2,318 (71.24) |
| Infections with a predominantly sexual mode of transmission (A50-A64) | 0 (0.00) | 1 (0.04) | 1 (0.04) | 2 (0.07) | 3 (0.10) | 2 (0.06) |
| Other spirochaetal diseases (A65-A69) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 1 (0.03) | 0 (0.00) | 0 (0.00) |
| Other diseases caused by chlamydiae (A70-A74) | 0 (0.00) | 2 (0.08) | 1 (0.04) | 3 (0.10) | 5 (0.16) | 0 (0.00) |
| Rickettsioses (A75-A79) | 9 (0.41) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 13 (0.04) |
| Viral infections of the central nervous system (A80-A89) | 19 (0.87) | 16 (0.62) | 13 (0.51) | 9 (0.30) | 21 (0.67) | 20 (0.61) |
| Arthropod-borne viral fevers and viral hemorrhagic fevers (A92-A99) | 6 (0.28) | 4 (0.16) | 10 (0.39) | 8 (0.27) | 4 (0.13) | 7 (0.22) |
| Viral infections characterized by skin and mucous membrane lesions (B00-B09) | 4 (0.18) | 7 (0.27) | 8 (0.31) | 10 (0.34) | 5 (0.16) | 10 (0.31) |
| Viral hepatitis (B15-B19) | 114 (5.23) | 138 (5.38) | 159 (6.21) | 125 (4.23) | 101 (3.20) | 108 (3.32) |
| Human immunodeficiency virus [HIV] disease (B20-B24) | 17 (0.78) | 16 (0.62) | 9 (0.35) | 6 (0.20) | 6 (0.19) | 7 (0.22) |
| Other viral diseases (B25-B34) | 2 (0.09) | 7 (0.27) | 4 (0.16) | 7 (0.24) | 5 (0.16) | 7 (0.22) |
| Mycoses (B35-B49) | 21 (0.96) | 38 (1.48) | 28 (1.09) | 37 (1.25) | 55 (1.74) | 72 (2.21) |
| Protozoal diseases (B50-B64) | 6 (0.28) | 12 (0.47) | 8 (0.31) | 15 (0.51) | 0 (0.00) | 0 (0.00) |
| Helminthiases (B65-B83) | 2 (0.09) | 0 (0.00) | 1 (0.04) | 2 (0.07) | 2 (0.06) | 1 (0.03) |
| Pediculosis, acariasis, and other infestations (B85-B89) | 0 (0.00) | 0 (0.00) | 2 (0.08) | 2 (0.07) | 0 (0.00) | 0 (0.00) |
| Sequelae of infectious and parasitic diseases (B90-B94) | 54 (2.48) | 46 (1.79) | 50 (1.95) | 29 (0.98) | 21 (0.67) | 37 (1.14) |
| Bacterial, viral, and other infectious agents (B95-B98) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) |
| Other infectious diseases (B99) | 4 (0.18) | 7 (0.27) | 2 (0.08) | 9 (0.30) | 10 (0.32) | 5 (0.15) |
| Diseases of the respiratory system (J00-J99) | 2017 (N = 9,441) |
2018 (N = 11,181) |
2019 (N = 11,364) |
2020 (N = 11,315) |
2021 (N = 11,648) |
2022 (N = 13,368) |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Acute upper respiratory infections (J00-J06) | 9 (0.10) | 9 (0.08) | 5 (0.04) | 6 (0.05) | 2 (0.02) | 8 (0.06) |
| Influenza and pneumonia (J09-J18) | 5,681 (60.17) | 7,075 (63.28) | 7,253 (63.82) | 7,126 (62.98) | 7,247 (62.22) | 8,626 (64.53) |
| Other acute lower respiratory infections (J20-J22) | 18 (0.19) | 13 (0.12) | 12 (0.11) | 10 (0.09) | 10 (0.09) | 12 (0.09) |
| Other diseases of the upper respiratory tract (J30-J39) | 10 (0.11) | 16 (0.14) | 9 (0.08) | 10 (0.09) | 16 (0.14) | 12 (0.09) |
| Chronic lower respiratory diseases (J40-J47) | 1,947 (20.62) | 1,949 (17.43) | 1,953 (17.19) | 1,726 (15.25) | 1,707 (14.65) | 1,950 (14.59) |
| Lung diseases due to external agents (J60-J70) | 916 (9.70) | 1,080 (9.66) | 1,079 (9.49) | 1,300 (11.49) | 1,350 (11.59) | 1,315 (9.84) |
| Other respiratory diseases principally affecting the interstitium (J80-J84) | 477 (5.05) | 534 (4.78) | 540 (4.75) | 542 (4.79) | 637 (5.47) | 732 (5.48) |
| Suppurative and necrotic conditions of the lower respiratory tract (J85-J86) | 70 (0.74) | 88 (0.79) | 90 (0.79) | 81 (0.72) | 96 (0.82) | 86 (0.64) |
| Other diseases of the pleura (J90-J94) | 54 (0.57) | 77 (0.69) | 72 (0.63) | 75 (0.66) | 107 (0.92) | 94 (0.70) |
| Other diseases of the respiratory system (J95-J99) | 259 (2.74) | 340 (3.04) | 351 (3.09) | 439 (3.88) | 476 (4.09) | 533 (3.99) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
